Table 2.

Association between GZMB genotype and clinical outcome

Parameter	Test variables	Univariate analysis		Multivariate analysis
		HR (95% CI)	P value	HR (95% CI)	P value
PFS
GZMB c.128T>C	CC+CT vs TT	1.39 (1.07 to 1.80)	0.013*	1.38 (1.02 to 1.87)	0.036*
WHO	0 vs ≥1	0.66 (0.46 to 0.95)	0.027*	0.61 (0.42 to 0.89)	0.01*
Sex	Male vs female	1.38 (1.06 to 1.80)	0.018*	1.29 (0.95 to 1.76)	0.103
OS
GZMB c.128T>C	CC+CT vs TT	1.19 (0.91 to 1.57)	0.212
WHO	0 vs ≥1	0.52 (0.35 to 0.77)	0.001*
Sex	Male vs female	1.40 (1.05 to 1.86)	0.023*

Parameter	Test variables	Univariate analysis		Multivariate analysis
		OR (95% CI)	P value	OR (95% CI)	P value
BOR
GZMB c.128T>C	CC +CT vs TT	1.63 (1.04 to 2.57)	0.033*	1.60 (1.01 to 2.52)	0.044*
Primary tumor	Other vs adeno	0.63 (0.40 to 0.98)	0.041*	0.63 (0.41 to 0.99)	0.045*

Univariate and multivariate analysis of the association of germline variation of GZMB and PFS, OS, or BOR. Patient factors associated with OS/PFS (p value<0.1) were included in the multivariate analysis. Significance is marked by *.

BOR, best overall response; OS, overall survival; PFS, progression-free survival; WHO, WHO performance status.